Atara Biotherapeutics () director Brian N. Cherry purchased 104,166 shares of the company’s common stock on September 4, 2026. The transaction was executed at a price of $9.6 per share, totaling approximately $999,993. The purchase comes as the stock trades

Jonathan Vassil, Chief Revenue Officer at Toast, Inc. (), sold shares of the company’s Class A Common Stock totaling $484,056 on September 2, 2026. The sales followed the exercise of stock options. Mr. Vassil disposed of a total

Christopher D. Brown, a Director at 908 Devices Inc. (), recently sold shares of the company’s common stock. The transactions occurred on September 2, 2026. Mr. Brown disposed of 30,000 shares of common stock for a total value of $317,400.

Matthew M. Kim, comptroller at Southern Co (), recently sold shares of the company’s common stock. The transaction, which took place on September 3, 2026, involved the disposition of 1,400 shares of Southern Company common stock. The shares

Keith R. Larson, a director at NWPX Infrastructure, Inc., disposed of shares in the company on September 3, 2026. Larson sold 4 shares of NWPX common stock () for a total value of $443. The shares were sold at prices

, a 10% owner and director of AFLAC INC (), sold 13,500 shares of common stock on September 2, 2026. The transactions totaled $1,582,065, with shares sold at prices ranging from $116.67 to $117.50 per share. The reported weighted average price for these sales

Scott Bizily, Chief Legal Officer at 4D Molecular Therapeutics, Inc. (), recently sold shares worth $8,176 after exercising stock options, according to a Form 4 filing with the Securities and Exchange Commission. On September 1, 2026, Mr. Bizily acquired 584 shares

Chantelle Breithaupt, Senior Vice President and Chief Financial Officer of Arista Networks (), disposed of 612 shares of the company’s common stock on September 1, 2026. The shares were sold at a price of $195.77 per share, totaling $119,811. The